Journal article
A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
Abstract
Abstract.Objective: To investigate the pharmacokinetics and safety of afelimomab, a murine antibody fragment against human tumor necrosis factor (TNF)-α in patients with sepsis. Design: Multicenter, randomized, open-label, placebo-controlled phase I/II clinical trial. Setting: Intensive care units of six academic medical centers in the United States. Patients: Forty-eight patients with a clinical diagnosis of sepsis who received standard …
Authors
Gallagher J; Fisher C; Sherman B; Munger M; Meyers B; Ellison T; Fischkoff S; Barchuk WT; Teoh L; Velagapudi R
Journal
Intensive Care Medicine, Vol. 27, No. 7, pp. 1169–1178
Publisher
Springer Nature
Publication Date
July 2001
DOI
10.1007/s001340100973
ISSN
0342-4642